NCT07400458 Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration
| NCT ID | NCT07400458 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Pharmicell Co., Ltd. |
| Condition | Acute Myocardial Infarction |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2022-03-03 |
| Primary Completion | 2028-10-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2022-03-03 with a primary completion date of 2028-10-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This Long-term follow-up is designed to evaluate the safety of patient with Acute Myocardial Infarction who had administered Hearticellgram-AMI.
Eligibility Criteria
Inclusion Criteria: 1. Those who had administered Hearticellgram-AMI 2. Those who voluntarily agreed in writing to participate in this investigation Exclusion Criteria: \-
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07400458 clinical trial?
This trial is open to participants of all sexes, studying Acute Myocardial Infarction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07400458 currently recruiting?
Yes, NCT07400458 is actively recruiting participants. Contact the research team at daeun4100@pharmicell.com for enrollment information.
Where is the NCT07400458 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT07400458 clinical trial?
NCT07400458 is sponsored by Pharmicell Co., Ltd.. The trial plans to enroll 100 participants.